Global Point of Care
NMP22® BladderChek® 檢驗是一種快速、使用簡單的非侵入性檢驗方法，可配合標準診斷程序，用來輔助膀胱癌的診斷及監測。在就醫 30 分鐘內可得出結果，這意味著患者在前往診室訪視期間即可獲得結果，因此該檢驗提供了一種快速而實惠的輔助手段，幫助有罹患膀胱癌風險的患者進行檢測。
CE 標記，CLIA 豁免
美國 FDA 認可，可供專業就診之用及依照處方在家使用。
NMP22® BladderChek® 檢驗提供範圍廣泛的產品優點：
即使在疾病初期階段，仍可使用 NMP22 特定檢驗檢測到 NMP22 水平的升高，使其成為與標準診斷程序相配合的早期診斷和監測的理想指標。1,2 NMP22® BladderChek® 檢驗的運作方式是藉由檢測尿液中核基質蛋白 (NMP22) 的含量，膀胱癌細胞釋放出的量比正常細胞要多。3
| NMP22® BladderChek® 檢驗 | 代碼 |
|---|---|
| NMP22® BladderChek®（24 次） | D1200E |
| NMP22® BladderChek® 品管套件（1 個陽性品管，1 個陰性品管） | D1250 |
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
